OncoCyte Corp (OCX) — Cash Flow-to-Debt Ratio
OncoCyte Corp (OCX) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2025, meaning its operating cash flow of $-5.86 Million could theoretically repay 0% of its total liabilities ($50.14 Million) in one year. See OncoCyte Corp (OCX) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
OncoCyte Corp Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for OncoCyte Corp across 12 annual periods. Also explore OCX net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for OncoCyte Corp (2013–2024)
Year-by-year debt coverage analysis for OncoCyte Corp. For market capitalisation and broader financial context, see OncoCyte Corp market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.44x | $-20.71 Million | $47.35 Million | ▲ +7.6% |
| 2023 | -0.47x | $-23.32 Million | $49.30 Million | ▲ +31.7% |
| 2022 | -0.69x | $-45.57 Million | $65.80 Million | ▼ -81.8% |
| 2021 | -0.38x | $-35.94 Million | $94.35 Million | ▲ +67.8% |
| 2020 | -1.18x | $-25.98 Million | $21.94 Million | ▲ +45.8% |
| 2019 | -2.19x | $-19.71 Million | $9.02 Million | ▼ -14.3% |
| 2018 | -1.91x | $-11.65 Million | $6.09 Million | ▲ +17.0% |
| 2017 | -2.30x | $-13.38 Million | $5.81 Million | ▼ -40.4% |
| 2016 | -1.64x | $-7.52 Million | $4.58 Million | ▲ +10.2% |
| 2015 | -1.83x | $-4.23 Million | $2.31 Million | ▼ -1066.6% |
| 2014 | -0.16x | $-1.16 Million | $7.43 Million | ▼ -3.1% |
| 2013 | -0.15x | $-710.00K | $4.67 Million | — |